By Michael Susin

AstraZeneca said Thursday that phase III studies showed that Imfinzi plus Imjudo provided a sustained and clinically meaningful overall survival benefit in patients with advanced liver cancer.

The pharmaceutical major said that data showed an overall survival benefit at four years for patients with unresectable hepatocellular carcinoma who hadn't received prior systemic therapy and weren't eligible for localized treatment.

The company added that the treatment reduced the risk of death by 22% compared to other treatments.

"Historically, only 7% of patients with advanced liver cancer have survived five years, making the [phase III clinical trial] Himalaya long-term survival data especially meaningful," lead Investigator in the trial Bruno Sangro said.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

June 29, 2023 09:46 ET (13:46 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.